H.C. Wainwright Remains a Hold on Amarin (AMRN)

H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Amarin (AMRNResearch Report) today and set a price target of $3.00. The company’s shares closed last Thursday at $1.28, close to its 52-week low of $1.11.

According to, Fein is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -11.2% and a 37.2% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Amarin has an analyst consensus of Hold, with a price target consensus of $2.80, a 124.0% upside from current levels. In a report released yesterday, SVB Securities also reiterated a Hold rating on the stock with a $3.00 price target.

See today’s best-performing stocks on TipRanks >>

Amarin’s market cap is currently $507.9M and has a P/E ratio of -23.19.

Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMRN in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Read More on AMRN:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More